Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059713088> ?p ?o ?g. }
- W2059713088 endingPage "1169" @default.
- W2059713088 startingPage "1169" @default.
- W2059713088 abstract "purpose. To evaluate the potential of topical iganidipine ophthalmic solution to exert Ca2+-antagonistic activity in the posterior parts of the eye without inducing systemic effects, ocular and periocular penetration of topically instilled iganidipine was studied in pigmented rabbits. method. First, 14C-iganidipine solution (0.03%, 30 μL) was instilled into one eye, and vehicle into the other eye to determine the intraocular penetration of iganidipine and to measure the radioactivity of ocular tissues 0.25, 0.5, 1, 2, 4, and 12 hours after a single instillation (n = 3, respectively). Second, iganidipine (0.03%) or betaxolol (0.5%) was unilaterally instilled twice daily for 20 days to study the effects on intravitreously injected various doses of endothelin (ET)-1-induced retinal artery constriction to evaluate whether a pharmacologically active level of the drug penetrated to the posterior retina and to estimate the drug level in the posterior retina (n = 6, respectively). Third, iganidipine (0, 10, or 30 μg/kg: n = 6, 3, and 6, respectively) was intravenously injected to study the effects on intravitreously injected ET-1-induced retinal artery constriction to evaluate iganidipine levels in the posterior retina. Fourth, periocular penetration of iganidipine was studied by means of whole-head autoradiography after a single instillation of 14C-iganidipine (0.09%, 30 μL; n = 5). results. Penetration of topically applied iganidipine to the cornea or aqueous humor was high and estimated to be at least 10 times higher than that reported for timolol or carteolol. Concentrations in the iris-ciliary body or retina-choroid were much higher than in the plasma, both in the treated and control eyes, suggesting that iganidipine binds to uveal pigments. Twice-daily 20-day instillation of iganidipine (0.03%), but not of betaxolol (0.5%), significantly suppressed constriction of the retinal arteries induced by intravitreous injection of ET-1 at a dose of 2.5 or 0.5 ng in the ipsilateral eye. Intravenous injection of iganidipine at a dose of 30 μg/kg (giving a free plasma concentration of approximately 10−8 M), but not at a dose of 10 μg/kg, significantly suppressed intravitreous ET-1-induced (0.5 ng) constriction of the retinal artery to a similar degree as twice-daily 20-day instillation of 0.03% iganidipine. After a single instillation of 0.09% iganidipine, the equivalent concentration of iganidipine in the ipsilateral retrobulbar periocular space estimated from autoradiography was approximately 3.9 × 10−8 M between 15 minutes and 1 hour after instillation, consistently higher than in the untreated contralateral eyes by approximately 3.0 × 10−8 M (P = 0.043). conclusions. In rabbits, topically instilled iganidipine, a Ca2+ antagonist, in a 0.03% solution reaches the ipsilateral posterior retina or retrobulbar periocular space by local penetration at concentrations sufficient to act as a Ca2+ antagonist." @default.
- W2059713088 created "2016-06-24" @default.
- W2059713088 creator A5027927756 @default.
- W2059713088 creator A5039770030 @default.
- W2059713088 creator A5048087220 @default.
- W2059713088 creator A5052312954 @default.
- W2059713088 creator A5054263523 @default.
- W2059713088 creator A5065087596 @default.
- W2059713088 creator A5074724972 @default.
- W2059713088 date "2003-03-01" @default.
- W2059713088 modified "2023-10-11" @default.
- W2059713088 title "Iganidipine, a New Water-Soluble Ca<sup>2+</sup>Antagonist: Ocular and Periocular Penetration after Instillation" @default.
- W2059713088 cites W1518486951 @default.
- W2059713088 cites W1964505024 @default.
- W2059713088 cites W1970357151 @default.
- W2059713088 cites W1975807493 @default.
- W2059713088 cites W1981678742 @default.
- W2059713088 cites W1982832223 @default.
- W2059713088 cites W1999624163 @default.
- W2059713088 cites W2009161435 @default.
- W2059713088 cites W2017604806 @default.
- W2059713088 cites W2035446448 @default.
- W2059713088 cites W2042632071 @default.
- W2059713088 cites W2046894611 @default.
- W2059713088 cites W2049185697 @default.
- W2059713088 cites W2063134208 @default.
- W2059713088 cites W2066277442 @default.
- W2059713088 cites W2072684798 @default.
- W2059713088 cites W2075299947 @default.
- W2059713088 cites W2077441886 @default.
- W2059713088 cites W2083517919 @default.
- W2059713088 cites W2085642971 @default.
- W2059713088 cites W2100806280 @default.
- W2059713088 cites W2134528059 @default.
- W2059713088 cites W2149388724 @default.
- W2059713088 cites W2162804111 @default.
- W2059713088 cites W2168397955 @default.
- W2059713088 cites W2285732122 @default.
- W2059713088 cites W2410469280 @default.
- W2059713088 cites W2413144740 @default.
- W2059713088 cites W2460412099 @default.
- W2059713088 doi "https://doi.org/10.1167/iovs.02-0482" @default.
- W2059713088 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12601046" @default.
- W2059713088 hasPublicationYear "2003" @default.
- W2059713088 type Work @default.
- W2059713088 sameAs 2059713088 @default.
- W2059713088 citedByCount "24" @default.
- W2059713088 countsByYear W20597130882013 @default.
- W2059713088 countsByYear W20597130882014 @default.
- W2059713088 countsByYear W20597130882017 @default.
- W2059713088 countsByYear W20597130882020 @default.
- W2059713088 crossrefType "journal-article" @default.
- W2059713088 hasAuthorship W2059713088A5027927756 @default.
- W2059713088 hasAuthorship W2059713088A5039770030 @default.
- W2059713088 hasAuthorship W2059713088A5048087220 @default.
- W2059713088 hasAuthorship W2059713088A5052312954 @default.
- W2059713088 hasAuthorship W2059713088A5054263523 @default.
- W2059713088 hasAuthorship W2059713088A5065087596 @default.
- W2059713088 hasAuthorship W2059713088A5074724972 @default.
- W2059713088 hasConcept C118487528 @default.
- W2059713088 hasConcept C126322002 @default.
- W2059713088 hasConcept C127413603 @default.
- W2059713088 hasConcept C134018914 @default.
- W2059713088 hasConcept C158846371 @default.
- W2059713088 hasConcept C169760540 @default.
- W2059713088 hasConcept C174940676 @default.
- W2059713088 hasConcept C185592680 @default.
- W2059713088 hasConcept C2775926640 @default.
- W2059713088 hasConcept C2776694393 @default.
- W2059713088 hasConcept C2776882836 @default.
- W2059713088 hasConcept C2777093970 @default.
- W2059713088 hasConcept C2778073030 @default.
- W2059713088 hasConcept C2778434524 @default.
- W2059713088 hasConcept C2779108703 @default.
- W2059713088 hasConcept C2779938033 @default.
- W2059713088 hasConcept C2780662894 @default.
- W2059713088 hasConcept C2780827179 @default.
- W2059713088 hasConcept C2781092963 @default.
- W2059713088 hasConcept C42219234 @default.
- W2059713088 hasConcept C42475967 @default.
- W2059713088 hasConcept C71924100 @default.
- W2059713088 hasConcept C80107235 @default.
- W2059713088 hasConcept C86803240 @default.
- W2059713088 hasConceptScore W2059713088C118487528 @default.
- W2059713088 hasConceptScore W2059713088C126322002 @default.
- W2059713088 hasConceptScore W2059713088C127413603 @default.
- W2059713088 hasConceptScore W2059713088C134018914 @default.
- W2059713088 hasConceptScore W2059713088C158846371 @default.
- W2059713088 hasConceptScore W2059713088C169760540 @default.
- W2059713088 hasConceptScore W2059713088C174940676 @default.
- W2059713088 hasConceptScore W2059713088C185592680 @default.
- W2059713088 hasConceptScore W2059713088C2775926640 @default.
- W2059713088 hasConceptScore W2059713088C2776694393 @default.
- W2059713088 hasConceptScore W2059713088C2776882836 @default.
- W2059713088 hasConceptScore W2059713088C2777093970 @default.
- W2059713088 hasConceptScore W2059713088C2778073030 @default.
- W2059713088 hasConceptScore W2059713088C2778434524 @default.
- W2059713088 hasConceptScore W2059713088C2779108703 @default.